William Blair Weighs in on AbbVie's Q2 Earnings (NYSE:ABBV)

AbbVie Inc. (NYSE:ABBV - Free Report) - Investment analysts at William Blair dropped their Q2 2025 earnings estimates for AbbVie in a report released on Monday, July 14th. William Blair analyst M. Phipps now forecasts that the company will post earnings of $2.88 per share for the quarter, down from their prior forecast of $3.27. The consensus estimate for AbbVie's current full-year earnings is $12.31 per share.

ABBV has been the topic of a number of other reports. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $194.00 price target on shares of AbbVie in a research report on Tuesday, April 8th. BNP Paribas raised shares of AbbVie to a "hold" rating in a research report on Thursday, May 8th. Evercore ISI increased their price target on AbbVie from $204.00 to $205.00 and gave the company an "outperform" rating in a report on Monday, April 28th. Citigroup raised their price objective on AbbVie to $205.00 and gave the company a "hold" rating in a research report on Wednesday, June 11th. Finally, Morgan Stanley upped their target price on AbbVie from $241.00 to $250.00 and gave the stock an "overweight" rating in a research report on Monday, April 28th. Eight analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, AbbVie currently has a consensus rating of "Moderate Buy" and a consensus target price of $211.29.

AbbVie Trading Up 0.7%

NYSE:ABBV traded up $1.26 on Wednesday, hitting $191.84. 2,210,878 shares of the stock were exchanged, compared to its average volume of 6,313,572. The stock has a fifty day moving average of $186.95 and a 200-day moving average of $189.20. The stock has a market cap of $338.87 billion, a PE ratio of 81.61, a PEG ratio of 1.24 and a beta of 0.48. The company has a current ratio of 0.76, a quick ratio of 0.64 and a debt-to-equity ratio of 44.14. AbbVie has a fifty-two week low of $163.81 and a fifty-two week high of $218.66.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Friday, April 25th. The company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.40 by $0.06. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The company had revenue of $13.34 billion during the quarter, compared to analysts' expectations of $12.91 billion. During the same quarter in the previous year, the business earned $2.31 EPS. The firm's revenue was up 8.4% on a year-over-year basis.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be issued a $1.64 dividend. This represents a $6.56 annualized dividend and a yield of 3.42%. The ex-dividend date of this dividend is Tuesday, July 15th. AbbVie's dividend payout ratio is currently 279.15%.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Kelly Financial Services LLC grew its position in shares of AbbVie by 10.1% during the 2nd quarter. Kelly Financial Services LLC now owns 1,807 shares of the company's stock valued at $335,000 after buying an additional 166 shares during the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH grew its holdings in shares of AbbVie by 204.4% during the second quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 17,102 shares of the company's stock valued at $3,174,000 after purchasing an additional 11,484 shares during the last quarter. Moss Adams Wealth Advisors LLC grew its holdings in shares of AbbVie by 6.0% during the second quarter. Moss Adams Wealth Advisors LLC now owns 6,610 shares of the company's stock valued at $1,227,000 after purchasing an additional 373 shares during the last quarter. GC Wealth Management RIA LLC raised its position in shares of AbbVie by 292.2% during the 2nd quarter. GC Wealth Management RIA LLC now owns 29,969 shares of the company's stock worth $5,563,000 after purchasing an additional 22,327 shares during the period. Finally, Enclave Advisors LLC lifted its holdings in shares of AbbVie by 7.1% in the 2nd quarter. Enclave Advisors LLC now owns 3,557 shares of the company's stock worth $660,000 after purchasing an additional 235 shares during the last quarter. Institutional investors own 70.23% of the company's stock.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.